Peru - španělština - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

alkhofar sociedad anonima cerrada -

Peru - španělština - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

enervitalgreen s.a.c. -

Kuba - španělština - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

zhejiang tianrui pharmaceutical co., ltd. - cloruro de potasio - solución para inyección iv. - 1,5 g/10 ml

Evropská unie - španělština - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - esclerosis múltiple - inmunosupresores selectivos - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 y 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Evropská unie - španělština - EMA (European Medicines Agency)

mylan ireland limited - fingolimod clorhidrato de - la esclerosis múltiple remitente-recurrente - inmunosupresores - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 y 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Peru - španělština - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

world drug pharmaceutical s.a.c. -

Peru - španělština - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

corporacion castillo sociedad anonima - corpcas -